Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University203 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School87 Nanjing First Hospital, Nanjing Medical University72 Nanjing Medical University30 The Second Hospital of Nanjing Medical University30
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Nanjing

1211 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Sanofi
Phase 2
187
Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenyang
2022-11-25
Recruiting
Jinling Hospital, China
Phase 2
30
Nanjing
2022-11-23
Recruiting
Pfizer
Phase 3
1,060
Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai
2022-11-10
Active, closed
AstraZeneca
Phase 3
368
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
2022-11-10
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
50
Nanjing
2022-11-01
Recruiting
Bone Marrow Mononuclear Cells for the Repair of Severe Maxillofacial Bone Defects
NCT07852806Maxillofacial Bone Defect, Alveolar Bone Loss
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
20
Nanjing
2022-11-01
Active, closed
Jiangsu Cancer Institute & Hospital
Phase 2
55
Nanjing
2022-10-27
Active, closed
LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB
NCT05572957Non-ischemic Cardiomyopathy, Heart Failure, Left Bundle-Branch Block
DrugGDMT
The First Affiliated Hospital with Nanjing Medical University
Not applicable
50
Beijing, Fuzhou, Nanjing, Dalian, Chengdu, Wenzhou
2022-10-14
Active, closed
InxMed (Shanghai) Co., Ltd.
Phase 1/2
140
Hangzhou, Bengbu, Changsha, Fuzhou, Ganzhou, Nanjing, Wuhan, Xuzhou
2022-10-12
Recruiting
Peking Union Medical College Hospital
Observational
2,000
Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Hohhot, Nanjing, Nanchang
2022-10-01
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Chaoyang, Chengdu, Hangzhou, Jinhua, Nanjing, Wuhan
2022-09-19
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
381
Baotou, Beijing, Changchun, Guangzhou, Haikou, Luoyang, Nanchang, Nanjing
2022-09-16
Active, closed
Sinotau Pharmaceutical Group
Phase 3
196
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun
2022-08-31
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Hefei, Chongqing, Nanjing, Nanchang, Pingxiang, Changchun, Taiyuan, Chengdu
2022-08-04
Recruiting
Peking University First Hospital
Observational
3,000
Beijing, Guandong, Nanjing, Jinan
2022-08-01
Not yet open
Nanjing University of Traditional Chinese Medicine
Not applicable
90
Nanjing
2022-08-01
By invitation
The First Affiliated Hospital with Nanjing Medical University
Not applicable
30
Nanjing
2022-07-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
251
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2022-07-27
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
300
Nanjing
2022-07-17
Active, closed
GlaxoSmithKline
Phase 3
163
Beijing, Guangzhou, Hefei, Nanjing, Qingdao, Shanghai, Shenzhen, Wenzhou
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Guangzhou, Shantou, Shenzhen, Liuzhou, Haikou, Wuhan, Changsha, Nanjing
2022-07-14
Active, closed
INSPIRIS China PMCF Study
NCT05404880Aortic Valve Replacement
Edwards Lifesciences
Observational
255
Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Xi'an, Chengdu
2022-07-13
Recruiting
Nanjing First Hospital, Nanjing Medical University
Observational
150
Nanjing
2022-07-10
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Beijing, Nanjing, Shanghai
2022-07-08
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Chongqing, Shijiazhuang, Harbin, Changsha, Nanjing, Suzhou, Changchun, Kunming
2022-07-07
Recruiting
TAVR for Aortic Valve Disease
NCT05439863Aortic Valve Disease
Nanjing First Hospital, Nanjing Medical University
Observational
5,000
Nanjing
2022-07-01
Active, closed
Biotheus Inc.
Phase 1/2
42
Chongqing, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Yibin, Tianjin
2022-07-01
Recruiting
Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
NCT05597709Type 2 Diabetes Mellitus in Remission, Metabolic Associated Fatty Liver Disease
Wuxi Hisky Medical Technology Co Ltd
Observational
2,900
Nanjing
2022-07-01
By invitation
The Anorectal Center of Nanjing Hospital of Traditional Chinese Medicine
Early Phase 1
90
Nanjing
2022-07-01
Recruiting
The Jinling Cohort
NCT06011694Cancer, Multi Cancer Early Screening, Liquid Biopsy
Nanjing Shihejiyin Technology, Inc.
Observational
15,000
Nanjing
2022-06-15
Active, closed
Hoffmann-La Roche
Phase 3
60
Beijing, Changsha, Chongqing, Fuzhou, Hangzhou, Hefei, Linyi, Nanjing
2022-06-14
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
254
Beijing, Nanjing
2022-06-10
Recruiting
Zhu Weiming
Not applicable
138
Nanjing
2022-06-09
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Not applicable
72
Nanjing
2022-06-01
Recruiting
Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD
NCT05766449Chronic Hepatitis b, Non-alcoholic Fatty Liver Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
1,000
Nanjing
2022-06-01
Recruiting
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Phase 1
288
Beijing, Changsha, Ganzhou, Hangzhou, Hanzhou, Linyi, Nanjing
2022-06-01
Recruiting
Beijing Tiantan Hospital
Observational
200
Beijing, Zhengzhou, Nanjing
2022-05-25
Recruiting
Nanjing First Hospital, Nanjing Medical University
Observational
5,000
Nanjing
2022-05-24
Recruiting
Nanjing First Hospital, Nanjing Medical University
Not applicable
180
Nanjing
2022-05-23
Active, closed
A Study of AL8326 in Non-Small Cell Lung Cancer
NCT06794957Non-small Cell Lung Cancer
DrugAL8326
Advenchen Laboratories, LLC
Phase 1
158
Bengbu, Hefei, Xuancheng, Anyang, Zhengzhou, Wuhan, Nanjing, Hangzhou
2022-05-19
Recruiting
Actelion
Phase 3
280
Beijing, Changsha, Nanjing, Qingdao, Shanghai, Xi'an
2022-05-04
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
100
Nanjing
2022-05-01
Recruiting
Peking Union Medical College Hospital
Observational
20,000
Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Hangzhou
2022-04-29
By invitation
AstraZeneca
Phase 3
214
Beijing, Changsha, Hangzhou, Nanjing, Shanghai, Shenyang, Wenzhou, Xi'an
2022-04-19
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
29
Nanjing
2022-04-01
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Not applicable
1,968
Nanjing
2022-04
Not yet open
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
20
Hefei, Changzhou, Nanjing
2022-04
Recruiting
National Registry and Cohort Study of Pulmonary Vascular Disease
NCT05368467Pulmonary Arterial Hypertension
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Guangzhou, Nanjing, Tianjin, Beijing, Changsha, Chendu, Shenyang, Wuhan
2022-03-29
Active, closed
STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation
NCT05352074Slow Transit Constipation, Surgery
Third Military Medical University
Not applicable
252
Yuzhong, Lanzhou, Wuhan, Nanjing, Shengyang, Qingdao, Pudong, Xi’an
2022-03-27
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
80
Nanjing
2022-03-16
Recruiting
Nanjing First Hospital, Nanjing Medical University
Phase 4
150
Nanjing
2022-03-15
Recruiting
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Recruiting
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
NCT05584761Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-2, Secondary Acute Myeloid Leukemia
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2
50
Nanjing
2022-03-01
Active, closed
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
NCT05194995Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
DrugsGlecirasib·Cetuximab
Allist Pharmaceuticals, Inc.
Phase 1/2
48
Beijing, Nanning, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2022-02-17
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
100
Nanjing
2022-02-01
Active, closed
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
193
Nanjing
2022-02-01
Recruiting
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
NCT05334823Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 2
100
Beijing, Chongqing, Shenzhen, Wuhan, Changsha, Nanjing, Suzhou, Nanchang
2022-01-26
Active, closed
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
50
Beijing, Fuzhou, Guangzhou, Wuhan, Changsha, Zhengzhou, Nanjing, Suzhou
2022-01-26
Recruiting
Second Xiangya Hospital of Central South University
Observational
20,000
Lanzhou, Shenzhen, Haikou, Harbin, Luoyang, Changsha, Nanjing, Changzhi
2022-01-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2022-01-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Early Phase 1
24
Nanjing
2022-01-01
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Recruiting
Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death
NCT06856993Sudden Cardiac Death, Exosome Multiomics, Clinical Prognosis
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
300
Nanjing
2021-12-22
Active, closed
Sanofi
Phase 4
1,339
Beijing, Dongguan, Guangzhou, Guiyang, Hebei, Hefei, Nanchang, Nanjing
2021-12-16
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Wuhan, Nanjing, Yinchuan, Taiyuan, Hangzhou, Wenzhou, Beijing, Shanghai
2021-12-13
Recruiting
Corheart 6: Long-term Cohort Study
NCT07094919Heart Failure
China National Center for Cardiovascular Diseases
Not applicable
160
Shenzhen, Zhengzhou, Wuhan, Nanjing, Beijing, Shanghai
2021-12-12
Active, closed
Novartis Pharmaceuticals
Phase 3
153
Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Xuzhou, Changchun, Chengdu
2021-11-15
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Observational
222
Nanjing
2021-11-01
Active, closed
AstraZeneca
Phase 3
148
Beijing, Changsha, Chongqing, Harbin, Jinan, Nanjing, Shanghai, Shenyang
2021-10-28
Active, closed
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Recruiting
Bayer
Phase 1/2
430
Beijing, Fuzhou, Harbin, Wuhan, Changsha, Nanjing, Taizhou, Jinan
2021-10-25
Active, closed
Merck Sharp & Dohme LLC
Phase 1
45
Beijing, Guangzhou, Nanjing, Tianjin, Hangzhou
2021-10-13
Active, closed
Gilead Sciences
Phase 2
53
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing
2021-10-12
Active, closed
Beeline Medicines Corporation
Phase 2
248
Beijing, Shenzhen, Nanjing, Suzhou, Changchun, Dalian, Jinan, Jining
2021-10-11
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu
2021-10-06
Recruiting
Pfizer
Phase 3
893
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2021-10-04
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
168
Nanjing
2021-10-01
Active, closed
Nanfang Hospital, Southern Medical University
Observational
1,300
Chongqing, Guangzhou, Hebei, Changsha, Nanjing, Xuzhou, Nanchang, Changchun
2021-09-15
Recruiting
Zenith Epigenetics
Phase 2
200
Hefei, Chongqing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Shenyang
2021-09-08
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
102
Chongqing, Fuzhou, Ganzhou, Hangzhou, Harbin, Hefei, Mianyang, Nanjing
2021-08-31
Active, closed
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
NCT04807166Ovarian Neoplasms, Fallopian Tube Neoplasms, Neoplasms by Site, Genital Neoplasms, Female
DrugsCarboplatin/Paclitaxel·Anlotinib
Wenjun Cheng
Phase 2
56
Huai'an, Nanjing, Suzhou, Wuxi, Yancheng
2021-08-24
By invitation
Huashan Hospital
Observational
1,000
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Nanjing, Suzhou
2021-08-01
Active, closed
GlaxoSmithKline
Phase 3
72
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanjing, Shenyang, Suzhou
2021-07-28
Active, closed
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
290
Nanjing
2021-07-28
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
1,120
Nanjing
2021-07-20
Active, closed
Bristol-Myers Squibb
Phase 3
729
Bengbu, Beijing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Changzhou, Nanjing
2021-07-15
Active, closed
The First Affiliated Hospital with Nanjing Medical University
Observational
496
Nanjing, Qingdao
2021-07-10
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
200
Nanjing
2021-07-01
Recruiting
Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
NCT05775419Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, Side Effect of Drug
The First Affiliated Hospital with Nanjing Medical University
Not applicable
1,216
Nanjing
2021-06-30
Active, closed
The First Affiliated Hospital with Nanjing Medical University
Not applicable
683
Nanjing
2021-06-22
Active, closed
Novartis Pharmaceuticals
Phase 3
1,144
Nanjing, Xian, Chengdu, Beijing, Guangzhou, Shanghai, Tianjin
2021-06-09
Recruiting
The Second Hospital of Nanjing Medical University
Not applicable
200
Nanjing
2021-06-01
Active, closed
Jiangsu Cancer Institute & Hospital
Phase 3
242
Nanjing
2021-06-01
Recruiting
Nanjing First Hospital, Nanjing Medical University
Not applicable
210
Nanjing
2021-05-21
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2021-05-19
Active, closed
Pfizer
Phase 3
599
Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2021-05-12
Active, closed
Hoffmann-La Roche
Observational
800
Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Taiyuan
2021-05-10
Active, closed
Hoffmann-La Roche
Phase 3
557
Changsha, Fuzhou, Guangzhou, Hefei, Nanjing, Shanghai, Shenyang, Tianjin
2021-04-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Guangzhou, Changsha, Nanjing, Nantong, Shanghai
2021-04-21
Active, closed
Novartis Pharmaceuticals
Phase 3
345
Lanzhou, Foshan, Guangzhou, Shijiazhuang, Baotou, Hohhot, Nanjing, Nantong
2021-03-01
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
110
Nanjing
2021-03-01
Active, closed
Celgene
Phase 3
313
Guangzhou, Nanyang, Changsha, Nanjing, Nantong, Nanchang, Qingdao, Taiyuan
2021-02-25
Recruiting
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
NCT04532606Benzodiazepines, Bladder Cancer, Delirium, Surgery
DrugsRemimazolam·Propofol
Peking University First Hospital
Phase 4
1,128
Beijing, Beijin, Guiyang, Nanjing, Shanghai
2021-02-05
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2021-02-02
Recruiting
Nanjing Medical University
Not applicable
500
Beijing, Guangzhou, Nanjing, Chengdu
2021-02-01
Recruiting
The Second Hospital of Nanjing Medical University
Not applicable
200
Nanjing
2021-01-26
Active, closed
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Active, closed
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
59
Beijing, Fuzhou, Guanzhou, Zhengzhou, Nanjing, Shanghai, Tianjin, Hangzhou
2021-01-13
Recruiting
Biologics for Stricturing Crohn's Diseases
NCT05645055The Efficacy of Biologics for Stricturing Crohn's Diseases
Jinling Hospital, China
Observational
200
Nanjing
2021-01-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
210
Nanjing
2021-01-01
Active, closed
Yatian Liu
Not applicable
40
Nanjing
2021-01-01
Recruiting
Nanjing Medical University
Not applicable
300
Guangzhou, Nanjing, Qingdao, Chengdu, Beijing
2021-01-01
Active, closed
Novartis Pharmaceuticals
Observational
78
Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Kunming, Hangzhou, Beijing
2020-12-31
Active, closed
Pfizer
Phase 3
841
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Nanjing
2020-12-21
Active, closed
Daiichi Sankyo
Phase 3
605
Beijing, Changsha, Hangzhou, Hangzou, Heilongjiang, Henan, Hubei, Nanjing
2020-12-21
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Dongguan, Fuzhou, Baotou, Nanjing, Nantong, Shanghai, Chengdu, Ürümqi
2020-12-11
Active, closed
Zhongda Hospital
Observational
1,136
Nanjing
2020-10-28
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsCT041 autologous CAR T-cell·Apatinib·Irinotecan
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Active, closed
Hoffmann-La Roche
Phase 3
210
Beijing, Guangzhou, Hangzhou, Nanjing, Nantong, Shanghai, Wuhan
2020-10-08
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2020-09-23
Active, closed
AbbVie
Phase 3
531
Beijing, Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Suzhou
2020-09-10
Active, closed
Nanjing First Hospital, Nanjing Medical University
Not applicable
784
Nanjing
2020-09-08
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
DrugHH2853
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Hefei, Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha, Nanjing
2020-09-08
Active, closed
Xiamen University
Phase 3
9,327
Nanjing, Chengdu
2020-09-05
Active, closed
Karyopharm Therapeutics Inc
Phase 2/3
501
Nanjing, Suzhou, Huangpu, Xuhui, Chengdu, Hangzhou
2020-09-03
Active, closed
First Affiliated Hospital of Zhejiang University
Phase 3
232
Changsha, Chongqing, Hangzhou, Nanjing, Ningbo, Suzhou
2020-09-01
Recruiting
MR Microstructural Imaging for Prostate Cancer Diagnosis
NCT07249281Prostate Cancer, Diffusion MRI
First Affiliated Hospital of Zhejiang University
Observational
2,000
Beijing, Zhengzhou, Nanjing, Dalian, Hangzhou
2020-09-01
Recruiting
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
NCT06561906Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Subjective Cognitive Decline
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
1,000
Nanjing
2020-09-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Observational
339
Nanjing
2020-08-31
Active, closed
Sun Yat-sen University
Not applicable
1,124
Chongqing, Lanzhou, Guangzhou, Shenzhen, Guilin, Zhengzhou, Wuhan, Nanjing
2020-08-25
Active, closed
GlaxoSmithKline
Phase 3
242
Beijing, Changchun, Chongqing, Guangzhou, Nanchang, Nanjing, Shanghai, Tianjin
2020-07-14
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
537
Beijing, Guangzhou, Zhengzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2020-07-14
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
530
Nanjing
2020-06-29
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2
81
Nanjing
2020-06-09
Recruiting
Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)
NCT04230785Stroke, Acute, Stroke, Ischemic, Endovascular Treatment
Nanjing First Hospital, Nanjing Medical University
Observational
300
Nanjing
2020-03-15
Recruiting
Amgen
Phase 1
479
Beijing, Guangzhou, Nanchang, Shanghai, Hangzhou, Nanjing, Wenzhou
2020-03-04
Recruiting
Nanjing First Hospital, Nanjing Medical University
Observational
3,000
Nanjing
2020-02-25
Not yet open
Choroidal Change on OCTA in Eyes With High Myopia
NCT04255524Myopia, Progressive, Choroid Disease
The First Affiliated Hospital with Nanjing Medical University
Not applicable
200
Nanjing
2020-02-01
Recruiting
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
NCT05406999Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer, Intense Endocrine Therapy
DrugsRezvilutamide·Apalutamide·Abiraterone acetate·Enzalutamide
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
900
Nanjing
2020-02-01
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 1
276
Beijing, Guangdong, Shijiazhuang, Zhengzhou, Nanjing, Shenyang, Shanghai, Xian
2020-01-20
Active, closed
BeOne Medicines
Phase 3
955
Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2020-01-16
Recruiting
Fudan University
Not applicable
320
Nanjing, Shanghai
2020-01-06
Recruiting
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
NCT06926192Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
Peking Union Medical College
Observational
100
Nanjing
2020-01-01
Active, closed
JiAngSu Maternal and INfant HEalth Database
NCT06641479Pregnant Women, Children
Yang Zhao
Observational
1,570,360
Nanjing
2020-01-01
Recruiting
CAES for Internal Hemorrhoids and Rectal Prolapse
NCT04169152Internal Hemorrhoid, Rectal Prolapse
Faming Zhang
Observational
10,000
Nanjing
2019-12-30
Active, closed
Pfizer
Phase 3
1,068
Hefei, Beijing, Fuzhou, Wuhan, Changsha, Nanjing, Nantong, Suzhou
2019-12-30
Recruiting
Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)
NCT04175691Acute Stroke, Ischemic Stroke
Nanjing First Hospital, Nanjing Medical University
Observational
500
Nanjing
2019-11-24
Active, closed
Geneplus-Beijing Co. Ltd.
Observational
757
Beijing, Shenzhen, Zhengzhou, Changsha, Nanjing, Changchun, Jinzhou, Chengdu
2019-11-12
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Guangzhou, Zhanjiang, Zhengzhou, Changsha, Wuhan, Nanjing, Xuzhou, Nanchang
2019-10-02
Recruiting
Chemoradiotherapy in Unresectable Esophageal Cancer
NCT04278287Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel, Unresectable Malignant Neoplasm
DrugsAlbumin-Bound Paclitaxel·Nab-paclitaxel·Cisplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
105
Anyang, Changsha, Nanjing, Beijing
2019-10-01
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
DrugAST-3424
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Recruiting
Southeast University, China
Observational
200
Nanjing
2019-09-01
Active, closed
Nanjing First Hospital, Nanjing Medical University
Observational
2,600
Nanjing
2019-08-28
Active, closed
Nanjing First Hospital, Nanjing Medical University
Not applicable
3,710
Nanjing
2019-08-20
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Beijing, Changchun, Chengdu, Guangzhou, Haikou, Hangzhou, Lanzhou, Nanjing
2019-08-15
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Hefei, Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Xi'an
2019-08-09
Recruiting
Beijing Hospital
Not applicable
115
Beijing, Guangzhou, Harbin, Nanjing, Xuzhou, Changchun, Xi'an, Luzhou
2019-07-02
Active, closed
SyMap Medical (Suzhou), Ltd.
Not applicable
160
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Qiqihar, Nanjing, Suzhou, Xuzhou
2019-06-18
Recruiting
Eli Lilly and Company
Phase 3
190
Beijing, Chongqing, Nanjing, Suzhou
2019-04-05
Active, closed
Eisai Inc.
Phase 3
1,906
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Baotou, Nanjing, Changchun
2019-03-27
Active, closed
Intra-operative Pancreatoscopy in Patients With IPMN
NCT03729453Intraductal Papillary Mucinous Neoplasm
Boston Scientific Corporation
Observational
100
Nanjing
2019-03-20
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Ningbo, Shanghai
2019-01-25
Active, closed
Nanjing First Hospital, Nanjing Medical University
Not applicable
556
Nanjing
2018-12-26
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou, Changchun
2018-12-07
Active, closed
OBI Pharma, Inc
Phase 3
575
Beijing, Guangzhou, Nanning, Harbin, Wuhan, Changsha, Nanjing, Changchun
2018-12-05
Active, closed
AbbVie
Phase 3
265
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang, Shenyang
2018-10-22
Recruiting
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
NCT04592640Chronic Kidney Diseases, Calciphylaxis, Calcific Uremic Arteriolopathy, Treatment
The First Affiliated Hospital with Nanjing Medical University
Early Phase 1
9
Nanjing
2018-09-17
Active, closed
Janssen Research & Development, LLC
Phase 1
19
Beijing, Nanjing, Shanghai
2018-08-31
Active, closed
AbbVie
Phase 3
1,242
Hefei, Beijing, Guangzhou, Shijiazhuang, Wuhan, Changsha, Huaian, Nanjing
2018-08-28
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Haerbin, Nanjing, Hangzhou, Beijing, Hefei, Xiamen, Zhengzhou
2018-06-21
Active, closed
Exelixis
Phase 3
837
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2018-06-10
Recruiting
Zhongda Hospital
Observational
300
Nanjing
2018-06-01
Recruiting
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
NCT05461820Graves Disease, Relapse, Treatment, Drug Withdrawal
DrugMethimazole
The First Affiliated Hospital with Nanjing Medical University
Phase 4
240
Nanjing
2018-05-01
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
DrugsMevrometostat·Xtandi·Itraconazole·Enzalutamide
Pfizer
Phase 1
453
Guangzhou, Changsha, Nanjing, Chengdu, Wenzhou
2018-04-17
Active, closed
Children's Cancer Group, China
Phase 4
200
Chengdu, Nanjing, Shanghai
2018-04-01
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing
2018-03-23
Active, closed
AbbVie
Phase 3
747
Beijing, Xiamen, Guangzhou, Wuhan, Changsha, Nanjing, Nanchang, Changchun
2018-03-21
Recruiting
Microbiota Transplantation in Solid Organ Transplantation
NCT06730451Solid Organ Transplant Complications
The Second Hospital of Nanjing Medical University
Observational
50
Nanjing
2018-01-01
Active, closed
Pfizer
Phase 3
1,054
Hefei, Beijing, Fuzhou, Xiamen, Wuhan, Lianyungang, Nanjing, Nantong
2017-12-18
Active, closed
Daehwa Pharmaceutical Co., Ltd.
Phase 2/3
549
Hefei, Beijing, Guangzhou, Haikou, Harbin, Zhengzhou, Nanjing, Changchun
2017-12-18
Active, closed
Sanofi
Phase 3
475
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang
2017-12-07
Active, closed
CryoLife, Inc.
Not applicable
202
Beijing, Nanjing, Shanghai, Wuhan, Zhengzhou
2017-11-01
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2017-09-22
Active, closed
Eli Lilly and Company
Phase 3
5,637
Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Jinan
2017-07-12
Active, closed
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
360
Beijing, Wuhan, Changsha, Naning, Nanjing, Wuxi, Nanchang, Changchun
2017-05-12
Active, closed
AbbVie
Phase 3
443
Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Changchun, Shanghai
2017-02-02
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Hubei, Hunan, Nanjing
2016-12-22
Active, closed
The First Affiliated Hospital with Nanjing Medical University
Observational
500
Nanjing
2016-12
Recruiting
China Diabetes Cognitive Dysfunction Early Diagnosis and Intervention Study (China-DECODE Study)
NCT06650969Type 2 Diabetes, Subjective Cognitive Decline, Mild Cognitive Impairment, Dementia
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
10,000
Nanjing
2016-10-01
Active, closed
SyMap Medical (Suzhou), Ltd.
Not applicable
220
Beijing, Chongqing, Shenzhen, Shijiazhuang, Daqing, Wuhan, Nanjing, Xuzhou
2016-06-30
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanjing
2016-06
Recruiting
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
NCT06350825Metastatic Prostate Cancer, Therapy, Directly Observed
The First Affiliated Hospital with Nanjing Medical University
Phase 3
200
Nanjing
2016-01-01
Recruiting
Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome
NCT05397392Heart Failure, Kidney Diseases, Kidney Injury, Heart Valve Diseases
Nanjing First Hospital, Nanjing Medical University
Observational
1,200
Nanjing
2016-01
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai
2015-11-27
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2015-11-19
Active, closed
AstraZeneca
Phase 3
1,126
Beijing, Changchun, Changsha, Chongqing, Hangzhou, Nanjing, Shanghai, Shenyang
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
Beijing, Changchun, Dalian, Guangzhou, Hangzhou, Kunming, Nanjing, Nanning
2015-10-21
Active, closed
MedImmune LLC
Phase 2
433
Hangzhou, Nanjing, Shanghai
2015-10-19
Recruiting
Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
NCT03895593Intestinal Infection, Clostridioides Difficile Infection, Antibiotic-associated Diarrhea
The Second Hospital of Nanjing Medical University
Observational
100
Nanjing
2015-09-25
Active, closed
Hoffmann-La Roche
Phase 3
154
Beijing, Changchun, Chengdu, Hangzhou, Harbin, Nanjing, Shanghai, Shenyang
2015-02-02
Active, closed
Effects of Extracorporeal Treatment in Patients With Acute Poisoning
NCT06798129Poisoning, Extracorporeal Treatment
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
5,269
Nanjing
2015-01-01
Active, closed
AstraZeneca
Phase 3
1,837
Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing
2014-04-22
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1
60
Nanjing
2014-03-19
By invitation
Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
NCT04210791AL Amyloidosis, Plasma Cell Dyscrasia
Nanjing University School of Medicine
Observational
500
Nanjing
2010-07-01
Active, closed
Genentech, Inc.
Phase 2
378
Beijing, Changchun, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2008-10-16
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
20,000
Changzhou, Huai'an, Nanjing, Suqian, Suzhou
2008-01
Recruiting
Peking Union Medical College
Observational
2,000
Beijing, Chongqing, Guangzhou, Nanning, Shijiazhuang, Tianjin, Wuhan, Nanjing
2005-01
Recruiting
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
NCT04821778Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy
DrugNimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
2,000
Anyang, Changsha, Nanjing, Beijing
2002-01-01
Recruiting
Genzyme, a Sanofi Company
Observational
9,000
Beijing, Hangzhou, Jinan, Nanjing, Shanghai
2001-07-31
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai
1991-04-01
Rows per page Showing 1001–1211 of 1211
Previous 1 2 3
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,211 of those studies with a site in Nanjing.

How many clinical trials are recruiting in Nanjing?

725 of the 1,211 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 237 have not yet opened recruitment, 216 are active but closed to new participants, and 33 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.